Related Experiment Videos

Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants

    Pediatrics
    |February 5, 2002
    PubMed

    Insights

    Routine systemic dexamethasone is not recommended for preventing or treating chronic lung disease in very low birth weight infants. This statement reviews corticosteroid effects and offers guidance for healthcare professionals caring for neonates.

    Area of Science:

    • Neonatal medicine
    • Pediatric pulmonology
    • Pharmacology

    Background:

    • Chronic lung disease (CLD) is a significant concern in neonates, particularly those with very low birth weight (VLBW).
    • Postnatal corticosteroids are used to prevent or treat evolving or established CLD.
    • Understanding the short- and long-term effects of these treatments is crucial for clinical decision-making.

    Purpose of the Study:

    • To review the short- and long-term effects of systemic and inhaled postnatal corticosteroids.
    • To provide recommendations for the use of corticosteroids in VLBW infants with CLD.

    Main Methods:

    • This is a statement based on a review of existing literature and clinical evidence.
    • The focus is on evaluating the efficacy and safety of corticosteroid use in neonates.

    Main Results:

    • The routine use of systemic dexamethasone for CLD prevention or treatment in VLBW infants is not recommended.
    • Evidence regarding the benefits and harms of other corticosteroid regimens is also considered.

    Conclusions:

    • Healthcare professionals should carefully weigh the risks and benefits of corticosteroid use in VLBW infants.
    • Alternative strategies and judicious use of corticosteroids are emphasized for managing CLD.

    Related Concept Videos